Healius May Not Get the Strong 4Q It Needs -- Market Talk

2140 GMT - Pathology services provider Healius is banking on a strong 4Q to achieve its earnings guidance, but Jefferies is skeptical it can get there. In a note, analyst David Stanton says Healius's

WSJApr 4 05:40

Healius Price Target Cut 1.7% to A$1.18/Share by Jefferies

Healius Price Target Cut 1.7% to A$1.18/Share by Jefferies

Dow JonesApr 4 05:32

Morgan Stanley Adjusts Healius' Price Target to AU$1 From AU$1.30, Keeps at Underweight

Healius (ASX:HLS) has an average rating of underperform and price targets ranging from AU$1 to AU$3, according to analysts polled by CapitalIQ. Price (AUD): $1.26, Change: $-0.03, Percent Change: -2.3

MT NewswiresMar 6 10:06

Healius Could Solve Near-Term Gearing Issue With Imaging Sale -- Market Talk

0101 GMT - Healius could solve its near-term gearing challenges by selling its imaging business, Citi analyst Mathieu Chevrier writes in a note. A sale of the imaging business could be the most likely

WSJMar 5 09:01

Healius Begins Strategic Review of Assets, Structure Under New CEO

ustralian pathology and imaging provider Healius has begun a strategic review of its assets and structure that it said would be aimed at maximizing shareholder value.

WSJMar 5 08:00

Beaten-up ASX 200 Stock Jumps 14% on CEO Resignation

Healius Ltd (ASX: HLS) shares are storming higher on Tuesday morning.

The Motley FoolMar 5 07:18